

CITELINE JAPAN AWARDS

TUESDAY, OCTOBER 22, 2024
PALACE HOTEL, TOKYO

FINANCING DEAL OF THE YEAR

This new Award seeks to reward successful and creative fundraising by pharma and biotech companies in Japan, which are either privately or publicly owned. The investment can take various forms, including grants and public-private partnership deals, to fundraising from venture capital and private equity partners and initial public offering. The majority of the new funds should be earmarked for use in drug discovery and/or company development.

The basic criterion for this award is the total amount of money raised at one time – for example in a Series A (or later) funding round or through an IPO – but other factors should be considered as well. For example:

- Did the financing attract a broad range of investor groups?
- Did investors include groups that do not normally invest in pharma/biotech?
- Were any particularly novel financial instruments or structures used?
- Was the financing/IPO successful despite being launched in a challenging overall environment?

Please complete the contact and entry sections and email to Natalia Kay, Senior Events Manager.
E: Natalia.Kay@citeline.com

Details of person submitting the entry:

Entering Company

Twitter handle of the entering company

Name of the person submitting this entry form

Website of the entering company

Organization of the person submitting this entry form (if different from 'Entering Company')

References

Include any links to online references that may support your entry

Email address

Entry summary: (approx. 250 words)

Please enter a summary of your entry, this may be used in Awards publicity material so please do not include any confidential information.

Entry: (approx. 1500 words)

Please use this box to submit your entry, referring to the questions in the category criteria.

Entry: Continued

